Biopharmaceutical business Dimerix (ASX:DXB) should see boosted recruitment rates in the UK for its trial of focal segmental glomerulosclerosis (FSGS) after it entered a collaboration with the largest rare kidney disease registry in the world, the UK's National Registry of Rare Kidney Diseases (RaDaR), according to a research note from Euroz Hartleys.
RaDaR has more than 34,500 rare kidney disease patients recruited from 109 hospitals in the UK, with plans to identify patients suitable for Phase 3 of Dimerix's trial, the note stated.
Euroz Hartleys maintained its speculative buy rating and AU$0.91 price target on Dimerix.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.